Risk Factors for Atrial Fibrillation Progression.

Atrial fibrillation Burden Dynamics Progression Risk factors Vulnerable substrate

Journal

Cardiac electrophysiology clinics
ISSN: 1877-9190
Titre abrégé: Card Electrophysiol Clin
Pays: United States
ID NLM: 101549998

Informations de publication

Date de publication:
03 2021
Historique:
entrez: 31 1 2021
pubmed: 1 2 2021
medline: 29 9 2021
Statut: ppublish

Résumé

Atrial fibrillation is a chronic, progressive condition that presents a major health burden. This review summarizes recent studies assessing atrial fibrillation progression and its associated risk factors, describes the mechanisms underlying atrial fibrillation progression, and discusses the clinical implications of the progressive nature of atrial fibrillation. Progression of atrial fibrillation burden, and clinical progression from paroxysmal to more advanced (persistent/permanent) forms is common, but progression rates are variable. Atrial fibrillation progression parallels progressive atrial remodeling induced by atrial fibrillation risk factors and atrial fibrillation itself, and is associated with worse clinical outcomes.

Identifiants

pubmed: 33516398
pii: S1877-9182(20)30113-1
doi: 10.1016/j.ccep.2020.10.011
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-209

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors have nothing to disclose.

Auteurs

Jordi Heijman (J)

Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, PO Box 5800, Maastricht 6202 AZ, The Netherlands. Electronic address: https://twitter.com/JordiHeijman.

Justin G L M Luermans (JGLM)

Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, PO Box 5800, Maastricht 6202 AZ, The Netherlands. Electronic address: https://twitter.com/JLuermans.

Dominik Linz (D)

Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, PO Box 5800, Maastricht 6202 AZ, The Netherlands. Electronic address: https://twitter.com/Dominik_Linz.

Isabelle C van Gelder (IC)

Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands.

Harry J G M Crijns (HJGM)

Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center+, PO Box 5800, Maastricht 6202 AZ, The Netherlands. Electronic address: hjgm.crijns@mumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH